

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Advisory Committee on Breast Cancer in Young Women (ACBCYW); Meeting

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of meeting.

**SUMMARY:** In accordance with the Federal Advisory Committee Act, the CDC announces the following meeting for the Advisory Committee on Breast Cancer in Young Women (ACBCYW). This meeting is open to the public, limited only by audio and web conference lines (100 audio and web conference lines available). The public is welcome to listen to the meeting by accessing the teleconference and web conference information below. Online Registration Required: All ACBCYW Meeting participants must register for the meeting online at least 5 business days in advance at [https://www.cdc.gov/cancer/breast/what\\_cdc\\_is\\_doing/conference.htm](https://www.cdc.gov/cancer/breast/what_cdc_is_doing/conference.htm). Please complete all the required fields before submitting your registration and submit no later than November 16, 2020.

**DATES:** The meeting will be held on November 20, 2020, from 8:00 a.m. to 1:00 p.m., EST.

**ADDRESSES:** The teleconference access is 1-888-606-5944, and the passcode is 8340472. The web conference access is <https://adobeconnect.cdc.gov/rwa641n3jrry/>.

**FOR FURTHER INFORMATION CONTACT:** Jeremy McCallister, Designated Federal Officer, National Center for Chronic Disease Prevention and Health Promotion, CDC, 5770 Buford Highway, NE, Mailstop S107-4, Atlanta, Georgia 30341, Telephone (404) 639-7989, Fax (770) 488-4760, Email: [acbcyw@cdc.gov](mailto:acbcyw@cdc.gov).

**SUPPLEMENTARY INFORMATION:** *Purpose:* The committee provides advice and guidance to the Secretary, HHS; the Assistant Secretary for Health; and the Director, CDC, regarding the formative research, development, implementation and evaluation of evidence-based activities designed to prevent breast cancer (particularly among those at heightened risk) and promote the early detection and support of young women who develop the disease. The advice provided by the Committee will assist in ensuring scientific quality, timeliness, utility, and dissemination of credible appropriate messages and resource materials.

*Matters to be Considered:* The agenda will include discussions on current topics related to breast cancer in young women. These will include Mental/Behavioral Health, Sexual Health, Genetics and Genomics, and Provider Engagement. Agenda items are subject to change as priorities dictate.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2020-21848 Filed 10-1-20; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Advisory Committee on Immunization Practices: Notice of Charter Renewal

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of charter renewal.

**SUMMARY:** This gives notice under the Federal Advisory Committee Act of October 6, 1972, that the Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention, Department of Health and Human Services, has been renewed for a 2-year period through April 1, 2022.

**FOR FURTHER INFORMATION CONTACT:** Amanda Cohn, M.D., Designated Federal Officer, Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention, Department of Health and Human Services, 1600 Clifton Road NE, Mailstop H24-8, Atlanta, Georgia 30329-4027, telephone (404) 639-6039, or fax (404) 315-4679.

**SUPPLEMENTARY INFORMATION:** The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and

Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2020-21851 Filed 10-1-20; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

#### Statement of Organization, Functions, and Delegations of Authority

**AGENCY:** Office on Trafficking in Persons, Administration for Children and Families, HHS.

**ACTION:** Notice.

**SUMMARY:** Statement of Organizations, Functions, and Delegations of Authority. The Administration for Children and Families (ACF) is restructuring the Office on Trafficking in Persons (OTIP) within the Office of the Assistant Secretary for Children and Families, ACF, into three divisions—Prevention, Protection, and Research and Policy—that report to the OTIP Director.

**FOR FURTHER INFORMATION CONTACT:** Katherine Chon, Director, Office on Trafficking in Persons, Administration for Children and Families, 330 C Street SW, Washington, DC 20202; (202) 401-9372.

**SUPPLEMENTARY INFORMATION:** This notice amends Part K of the Statement of Organization, Functions, and Delegations of Authority of the Department of Health and Human Services (DHSS), Administration for Children and Families (ACF), Office on Trafficking in Persons (OTIP). The Office of the Assistant Secretary for Children and Families established OTIP by an amendment to the Statement of Organization for ACF published at 80 FR 33269, June 11, 2015. The amendment added OTIP as a new office under the Office of the Assistant Secretary for Children and Families. OTIP is responsible for developing and implementing programs that assist both foreign and domestic victims of human trafficking as well as implementing anti-trafficking legislation, appropriations, and Administration-driven priorities. OTIP executes its mission through grant and contract awards and by leveraging government and public-private partnerships. OTIP executes these responsibilities with a combination of federal and contract staff, and

occasional graduate-level interns. Since its inception in June 2015, OTIP's responsibilities have expanded exponentially driven by new statutory requirements, increased appropriations, Executive Order directives, Administration-driven priorities, and emerging issues in the anti-trafficking field that have necessitated an increase in inter- and intra-agency collaboration.

The changes announced herein describe the restructuring of OTIP within the Office of the Assistant Secretary for Children and Families, ACF, into three divisions—Prevention, Protection, and Research and Policy—that report to the OTIP Director.

### **I. Under Chapter KA.20, the Office on Trafficking in Persons Makes the Following Changes**

*KA.10 E. Organization.* The Office on Trafficking in Persons (KAI): OTIP has the following three strategic goals: Establish a cohesive national human trafficking victim service delivery system; develop a culture of data-informed anti-trafficking programming and policymaking; and integrate survivor-informed anti-trafficking efforts into HHS prevention strategies. OTIP implements numerous legislatively mandated programs and policies to combat human trafficking. OTIP's activities are authorized by federal statutes including, but not limited to, the Trafficking Victims Protection Act, as amended and reauthorized; the Justice for Victims of Trafficking Act; the Preventing Sex Trafficking and Strengthening Families Act; the Frederick Douglass Trafficking Victims Prevention and Protection Reauthorization Act; and the Stop, Observe, Ask, and Respond to Health and Wellness Act (or the SOAR to Health and Wellness Act).

The OTIP Director reports to the Assistant Secretary, ACF. The Director provides strategic leadership and direction on anti-trafficking programs and policies, anti-trafficking prevention efforts, building health and human service capacity to respond to human trafficking, strategies to increase victim identification and access to services, and strengthen the long-term health and well-being outcomes of survivors of human trafficking. OTIP is responsible for the overall leadership of anti-trafficking programs and services under the purview of ACF, including, but not limited to, developing and implementing programs that assist both foreign and domestic victims of human trafficking as well as implementing anti-trafficking statutory, appropriations, and Administration-driven priorities.

OTIP has the following three divisions: Protection (victim assistance), Prevention (capacity building, prevention, and public awareness), and Research and Policy. A description of each of the proposed divisions follows.

#### *Protection Division*

The Protection Division is comprised of OTIP's victim service and assistance activities. It includes the Trafficking Victim Assistance Program, the Domestic Victims of Human Trafficking Programs, the Child Eligibility and Adult Certification programs, Child Victim Coordination Activities, and the National Human Trafficking Hotline. Through a combination of grant activities and internal direct services, OTIP assists adult and minor, foreign and domestic victims of severe forms of trafficking in persons and participates in intra- and inter-agency coordination efforts to inform anti-trafficking program and policy development to improve our response to victims and efficiency in federally supported programming.

#### *Prevention Division*

The Prevention Division develops cutting-edge training and technical assistance, promotes survivor engagement, raises public awareness, facilitates regional outreach and coordination, and disseminates prevention education resources with the ultimate goal of assisting communities and programs in building capacity to effectively identify victims, implement trafficking prevention efforts, and coordinate education and outreach efforts. The Division oversees the National Human Trafficking Training and Technical Assistance Center, prevention education programming and the National Prevention Action Plan, the SOAR to Health and Wellness program, and the Look Beneath the Surface Public Awareness Campaign and Communication that includes OTIP's website content and conference and meeting planning and representation.

#### *Research and Policy Division*

The Research and Policy Division is responsible for the identification, coordination, and implementation of the anti-trafficking research agenda and policy development activities. The Division coordinates program evaluation and research, prepares documentation to comply with regulatory requirements, reviews and analyzes proposed legislation, develops and tracks program performance metrics, represents OTIP at internal and external data and policy events, provides technical support for data collection efforts, guides the

development of program information systems, prepares annual and ad hoc reports and informational materials, and ensures program development is evidence-based and theory-driven through research and evaluation efforts.

**Linda K. Hitt,**

*Executive Secretariat Certifying Officer.*

[FR Doc. 2020–21807 Filed 10–1–20; 8:45 am]

**BILLING CODE 4184–47–P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **Food and Drug Administration**

[Docket No. FDA–2018–D–2382]

#### **Opioid Use Disorder: Endpoints for Demonstrating Effectiveness of Drugs for Treatment; Guidance for Industry; Availability**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of availability.

**SUMMARY:** The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled “Opioid Use Disorder: Endpoints for Demonstrating Effectiveness of Drugs for Treatment.” This guidance addresses clinical endpoints acceptable to demonstrate effectiveness of drugs for treatment of opioid use disorder. This guidance addresses comments received for and finalizes the draft guidance of the same name issued August 7, 2018.

**DATES:** The announcement of the guidance is published in the **Federal Register** on October 2, 2020.

**ADDRESSES:** You may submit either electronic or written comments on Agency guidances at any time as follows:

#### *Electronic Submissions*

Submit electronic comments in the following way:

- *Federal eRulemaking Portal:* <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov> will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact